Somatostatin Receptor Imaging with68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation
Top Cited Papers
- 1 March 2015
- journal article
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 35 (2), 500-516
- https://doi.org/10.1148/rg.352140164
Abstract
Gallium 68 ((68)Ga) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-octreotate (DOTATATE, GaTate) positron emission tomography (PET)/computed tomography (CT) is an imaging technique for detecting and characterizing neuroendocrine tumors (NETs). GaTate, a somatostatin analog, has recently been accorded orphan drug status by the U.S. Food and Drug Administration, thereby increasing interest in and availability of this radiotracer. GaTate PET/CT allows whole-body imaging of cell surface expression of somatostatin receptors (SSTRs) and is rapidly evolving as the new imaging standard of reference for the detection and characterization of NETs. The authors discuss the normal appearance at GaTate PET/CT and the utility of this modality in a variety of these tumors, including gastrointestinal, pancreatic, and bronchial NETs as well as pheochromocytoma, paraganglioma, meningioma, and oncogenic osteomalacia. In addition, they discuss potential causes of false-positive findings, including pancreatic uncinate process activity, inflammation, osteoblastic activity, and splenosis. They also highlight the complementary role of 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) PET/CT, including the advantages of using both GaTate PET/CT and FDG PET/CT to evaluate sites of well- and poorly differentiated disease. The use of GaTate PET/CT together with FDG PET/CT allows identification of tumor heterogeneity, which provides prognostic information and can be pivotal in guiding biopsy. It also allows optimal patient management, including theranostic application of peptide receptor radionuclide therapy, and the restaging of patients following therapy.Keywords
This publication has 43 references indexed in Scilit:
- Measured Human Dosimetry of68Ga-DOTATATEJournal of Nuclear Medicine, 2013
- Is there still a role for SPECT–CT in oncology in the PET–CT era?Nature Reviews Clinical Oncology, 2012
- 68Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with18F-FDG, calcium burden and risk factorsEJNMMI Research, 2012
- Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningiomaRadiation Oncology, 2012
- 177Lu-DOTATATE Molecular Radiotherapy for Childhood NeuroblastomaJournal of Nuclear Medicine, 2011
- I-123 MIBG Scintigraphy and 68Ga-DOTANOC PET/CT Negative But F-18 DOPA PET/CT Positive PheochromocytomaClinical Nuclear Medicine, 2011
- 68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine TumorsJournal of Nuclear Medicine, 2010
- 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine TumorsClinical Cancer Research, 2010
- Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancyCancer Imaging, 2010
- Impact of Multiphase 68Ga-DOTATOC-PET/CT on Therapy Management in Patients with Neuroendocrine TumorsNeuroendocrinology, 2009